About AEI My AEI Support AEI Contact AEI
Home Events Books Short Publications Research Areas Scholars & Fellows


Search


FindAdvanced Search

Browse all books by:
- Date
- Subject
- Author
- Title

BOOKS
About the AEI Press
Orders and Shipping
Book Reviews
Press Releases

E-NEWSLETTERS
Enter e-mail:
 

Home >  Books >  Competitive Strategies in the Pharmaceutical Industry
Competitive Strategies in the Pharmaceutical Industry
Print Mail
Edited by Robert B. Helms
Posted: Saturday, January 1, 2000
Competitive Strategies in the Pharmaceutical Industry
Dimensions: 9.5'' x 6.5''
400 pages
AEI Press  (Washington)
Publication Date: June 1996
Paperback
ISBN: 0844738832
Hardcover
ISBN: 0844738824

The growth of government programs and managed care has altered how pharmaceuticals are marketed and sold in the United States. Such change has shortened the expected revenue stream from most products--even though new technologies have increased both the cost and the medical attractiveness of those products.

Managers of government and private health care programs are looking for new ways to reduce the cost of drug benefits, while company R&D managers are seeking ways to speed the regulatory process and develop new markets to cover the increasing cost of research.

This volume examines various aspects of the continuing policy dispute and offers several views on the future of the pharmaceutical industry.

Robert B. Helms is a resident scholar at AEI.



Table of Contents

  1. Introduction
  2. Generics and the Producer Price Index for Pharmaceuticals
  3. An Updated and Extended Study of the Price Growth of Prescription Pharmaceutical Preparations
  4. Measuring Quality Change in the Market for Anti-Ulcer Drugs
  5. The Uses and Abuses of International Price Comparisons
  6. Industrial Policy and International Competitiveness in the Pharmaceutical Industry
  7. R&D Productivity and Global Market Share in the Pharmaceutical Industry
  8. The Determinants of Research Productivity in Ethical Drug Discovery
  9. Prospects for Returns to Pharmaceutical R&D under Health Care Reform
  10. Measuring Pharmaceutical Industry Risk and the Cost of Capital
  11. The Effects of Research and Promotion on Rates of Return
  12. New Uses for Old Drugs
  13. The Leverage Principle in FDA's Regulation of Information
  14. Costs and Benefits of Cost-Benefit Analysis in Pharmaceutical Promotion and Utilization Decisions

Related Links
Health Policy Project
Order from Barnes and Noble
AEI Print Index No. 7531


Also by Robert B. Helms
Recent Articles
Fundamental Insurance Changes Needed to Reform American Healthcare
State Fiscal Relief
The SCHIP Open
Latest Book
Medicare in the Twenty-First Century
Seeking Fair and Efficient Reform
Real Education
Real Education

In his new book, Real Education: Four Simple Truths for Bringing America's Schools Back to Reality, AEI's Charles Murray focuses on four simple, hard truths that are rarely discussed or even acknowledged by educators and politicians.


Gross National Happiness
Gross National Happiness

In this provocative new book, Arthur C. Brooks explodes the myths about happiness in America. He examines vast amounts of evidence and empirical research to uncover the truth about who is happy in America, who is not, and why.